BioSpace News Archive

PharmaMar Has Published the Results of its Antibody Conjugate Active in Breast, Ovarian and Gastric Cancers that Express HER2

PharmaMar has announced the positive results of MI130004, a novel antibody conjugate combining trastuzumab with PM050489, a molecule of marine origin.

February 16, 2018

·

1 min read

Drug Development

Glenmark Pharma Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting

The GBR 830 Phase 2a study was a double-blind, placebo-controlled study in adults with moderate-to-severe atopic dermatitis that evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830.

February 16, 2018

·

3 min read

Business

Promore Pharma Regains Rights for PXL01 Manufacturing

Promore Pharma today announced that it will assume responsibility for the manufacturing of the investigational medicinal product for the clinical Phase III trial for PXL01 and at the same time, the company regains the global manufacturing rights for the commercial product.

February 16, 2018

·

5 min read

Business

Immuron: Travelan Revenue Grows Significantly in U.S. and Australia

Travelan experienced strong sales growth in both the U.S. and Australian markets throughout the first half of the 2018 financial year.

February 16, 2018

·

3 min read

Business

Arcturus Therapeutics Comments on Amended 13D Filing

As part of the amended 13D filing, Mr. Payne has proposed to nominate four director candidates and requested to convene an extraordinary general meeting.

February 16, 2018

·

4 min read

Pharm Country

amfAR Renews Investment in Bioengineering Approaches to Curing HIV

Totaling nearly $1M, the Investment grants will allow two collaborative teams of HIV researchers and bioengineers to embark on a second phase of projects initiated with amfAR funding awarded in February 2017.

February 16, 2018

·

3 min read

Drug Development

Xeris Pharmaceuticals Achieves Phase III Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia

Xeris has successfully completed two Phase 3 clinical studies of its investigational ready-to-use glucagon rescue pen (adult study: NCT02656069; pediatric study: NCT03091673).

February 16, 2018

·

4 min read

Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares

Jefferies LLC and Wells Fargo Securities, LLC are acting as joint book-running managers.

February 16, 2018

·

3 min read

Pharm Country

Amicus Therapeutics Prices Underwritten Offering of Common Stock

The offering is expected to close on February 21, 2018, subject to customary closing conditions.

February 16, 2018